Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of
MorphoSys AG replacing the current CEO and CFO

EQS-Ad-hoc: MorphoSys AG / Key word(s): Personnel
Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of
MorphoSys AG replacing the current CEO and CFO

06-Jun-2024 / 22:19 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Publication of an inside information according to Article 17 para. 1 of the
Regulation (EU) No. 596/2014

Planegg/Munich, Germany, June 6, 2024

Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of
MorphoSys AG replacing the current CEO and CFO

Following the closing of the takeover offer by Novartis BidCo AG to the
shareholders of MorphoSys AG (the 'Company') (FSE: MOR; NASDAQ: MOR) and the
resignation of Marc Cluzel, George Golumbeski, Krisja Vermeylen, Michael
Brosnan and Andrew Cheng from the Company's supervisory board, the Munich
Local Court appointed Heinrich Moisa, Romain Lege and Silke Mainka as new
members. The newly composed Supervisory Board held its first meeting today
and resolved to appoint Arkadius Pichota and Lukas Gilgen to the Company's
management board. Arkadius Pichota, who until now served as President,
General Manager and Chairman of the Board of the Novartis subsidiary
Navigate BioPharma Services, Inc., has been appointed as the new CEO and
Lukas Gilgen, who until now served as Transaction Lead Enterprise Projects
with Novartis International AG, has been appointed as the new CFO. Jean-Paul
Kress's and Lucinda Crabtree's membership of the Company's Management Board
has ended today.

***

END OF AD HOC ANNOUNCEMENT


End of Inside Information

---------------------------------------------------------------------------

Information and Explanation of the Issuer to this announcement:

About MorphoSys

At MorphoSys, we are driven by our mission: More life for people with cancer.
As a global biopharmaceutical company, we develop and deliver innovative
medicines, aspiring to redefine how cancer is treated. MorphoSys is
headquartered in Planegg, Germany, and has its U.S. operations anchored in
Boston, Massachusetts. To learn more, visit us at www.morphosys.com and
follow us on Twitter at X and LinkedIn.

MorphoSys Forward-Looking Statements

This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve known and unknown risks and uncertainties, which might cause the
actual results, financial condition and liquidity, performance or
achievements of MorphoSys, or industry results, to be materially different
from any historic or future results, financial conditions and liquidity,
performance or achievements expressed or implied by such forward-looking
statements. In addition, even if MorphoSys' results, performance, financial
condition and liquidity, and the development of the industry in which it
operates are consistent with such forward-looking statements, they may not
be predictive of results or developments in future periods. Among the
factors that may result in differences are that MorphoSys' expectations may
be incorrect, the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements, MorphoSys' reliance on collaborations with
third parties, estimating the commercial potential of its development
programs, effects of the acquisition of MorphoSys by Novartis AG on
relationships with employees, other business partners or governmental
entities, that Novartis AG may not realize the potential benefits of the
acquisition of MorphoSys, potential operational difficulties with
integrating MorphoSys with Novartis AG and other risks indicated in the risk
factors included in MorphoSys' Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission, including the
Solicitation/Recommendation Statement on Schedule 14D-9 regarding the
acquisition of MorphoSys by Novartis AG. Given these uncertainties, the
reader is advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the date of
publication of this document. MorphoSys expressly disclaims any obligation
to update any such forward-looking statements in this document to reflect
any change in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based or that may
affect the likelihood that actual results will differ from those set forth
in the forward-looking statements, unless specifically required by law or
regulation.

For more information, please contact:

MorphoSys AG

Dr. Julia Neugebauer

Vice President, Global Head of Investor Relations

Tel: +49 (0)89 / 899 27 179

julia.neugebauer@morphosys.com


---------------------------------------------------------------------------

06-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        MorphoSys AG
                   Semmelweisstr. 7
                   82152 Planegg
                   Germany
   Phone:          +49 (0)89 899 27-0
   Fax:            +49 (0)89 899 27-222
   E-mail:         investors@morphosys.com
   Internet:       www.morphosys.com
   ISIN:           DE0006632003
   WKN:            663200
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate
                   Exchange; Nasdaq
   EQS News ID:    1920107

End of Announcement EQS News Service
---------------------------------------------------------------------------

1920107 06-Jun-2024 CET/CEST